AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01231074
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
Trial: NCT00344812
Drug: LAAM. buprenorphine and methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01012570
Drug: Application of Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab will be applied according to manufacture's instruction and official guidelines.
Trial: NCT00002635
Drug: aminocamptothecin
RxNorm normalized name: Aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00012038
Drug: irofulven
RxNorm normalized name: Irofulven
DrugBank: Irofulven (DB05786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03019289
Drug: pridopidine (90 mg)
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
Trial: NCT00537914
Drug: Omnitrope
RxNorm normalized name: Omnitrope
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
Trial: NCT00515892
Drug: CAT-8015 Immunotoxin
RxNorm normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01933971
Drug: Filgrastim test
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
Trial: NCT01933971
Drug: Filgrastim reference
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous
Trial: NCT02244801
Drug: darTreg infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.~Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects.
Trial: NCT02312258
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib capsules.
Trial: NCT00089999
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02597907
Drug: aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aprepitant 80 mg is given to all patients before surgery
Trial: NCT02597907
Drug: palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
Trial: NCT02597907
Drug: Ramosetron
RxNorm normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
Trial: NCT02570672
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
Trial: NCT00844740
Drug: Cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
Trial: NCT03720418
Drug: OXB-102
RxNorm normalized name: Oxbryta
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
Trial: NCT01108458
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: iv, 840 mg, 420 mg
Trial: NCT01108458
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, 150 mg
Trial: NCT02556437
Drug: HyQvia
RxNorm normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
Trial: NCT00792558
Drug: BMS-817378
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
Trial: NCT01303120
Drug: Femoral Nerve Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Bupivacaine 0.5%, perineurally as single shot
Trial: NCT01303120
Drug: Combined nerve blocks
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Bupivacaine 0.5%, perineurally as single shot
Trial: NCT00231673
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
Trial: NCT02912455
Drug: canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: encapsulated (gelatin capsule).
Trial: NCT01845337
Drug: Teysuno
RxNorm normalized name: Teysuno
DrugBank: Gimeracil (DB09257)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01712308
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004759
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004759
Drug: tirilazad
RxNorm normalized name: TIRILAZAD
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04505202
Drug: 0.12% chlorhexidine gluconate
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care
Trial: NCT04872244
Drug: Levonorgestrel Drug Implant Product
RxNorm normalized name: levonorgestrel Drug Implant Product
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intrauterine administration
Trial: NCT03328143
Drug: Lavender (Lavandula angustifolia)
RxNorm normalized name: lavender (Lavandula angustifolia)
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lavender (Lavandula angustifolia) is an essential oil.
Trial: NCT03738449
Drug: CKD-387
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT03738449
Drug: D484
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: reference drug
Trial: NCT03736343
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will complete two drinking sessions.
Trial: NCT00649363
Drug: Ondansetron Orally Disintegrating Tablets 8 mg
RxNorm normalized name: ondansetron Disintegrating Oral Tablet
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8mg, single dose fasting
Trial: NCT01807156
Drug: Tivozanib
RxNorm normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral medication given daily. No placebo.
Trial: NCT02012192
Drug: Ganetespib
RxNorm normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02012192
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00122590
Drug: nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00122590
Drug: lopinavir/r
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00122590
Drug: indinavir
RxNorm normalized name: Indinavir
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00122590
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01074892
Drug: Provera (medroxyprogesterone/progestin)
RxNorm normalized name: medroxyprogesterone Oral Tablet [Provera]
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
Trial: NCT01074892
Drug: Provera (medroxyprogesterone)
RxNorm normalized name: medroxyprogesterone Oral Tablet [Provera]
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg per oral tablet. One tablet per day for 6 months
Trial: NCT02237235
Drug: MMFS-202-302
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks
Trial: NCT00970216
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
Trial: NCT03648554
Drug: dulaglutide (TRULICITY®) 1.5 mg
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
Trial: NCT03559803
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
Trial: NCT04192656
Drug: Methylprednisolone Hemisuccinate
RxNorm normalized name: Methylprednisolone hemisuccinate
DrugBank: Methylprednisolone hemisuccinate (DB14644)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
Trial: NCT00757185
Drug: ganirelix acetate
RxNorm normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
Trial: NCT00757185
Drug: methyl testosterone
RxNorm normalized name: 7-beta,17-alpha-Dimethyl testosterone
DrugBank: Methyltestosterone (DB06710)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
Trial: NCT01833312
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anti-shivering treatment
Trial: NCT01833312
Drug: Pethidine
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anti-shivering treatment
Trial: NCT00192062
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00192062
Drug: vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02352987
Drug: Salicylic acid
RxNorm normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
Trial: NCT02450552
Drug: Ezogabine
RxNorm normalized name: Ezogabine
DrugBank: Ezogabine (DB04953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
Trial: NCT04300452
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Carbetocin after placental detachment
Trial: NCT04300452
Drug: Ergometrine Maleate
RxNorm normalized name: Ergometrine maleate
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of ergometrin after placental detachment
Trial: NCT02710305
Drug: oral hyoscine butyl bromide tablets plus lidocaine cream
RxNorm normalized name: Butyl Alcohol
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
Trial: NCT00007826
Drug: alum adjuvant
RxNorm normalized name: alum
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02412904
Drug: rFSH
RxNorm normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
Trial: NCT00835328
Drug: Exendin (9-39)
RxNorm normalized name: EXENDIN (9-39)
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
Trial: NCT03838575
Drug: 2% alcoholic chlorhexidine skin prep (SKIN PREP)
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
Trial: NCT04181437
Drug: NVP-1203-R1
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet, Single oral dosing
Trial: NCT04181437
Drug: NVP-1203-R2
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet, Single oral dosing
Trial: NCT04181437
Drug: NVP-1203-R1 and NVP-1203-R2
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
Trial: NCT00770133
Drug: Naphazoline
RxNorm normalized name: Naphazoline
DrugBank: Naphazoline (DB06711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
Trial: NCT00770133
Drug: Ketotifen
RxNorm normalized name: Ketotifen
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
Trial: NCT03708588
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewed
Trial: NCT03708588
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integral
Trial: NCT02093663
Drug: MMX Mesalamine/Mesalazine (Low Dose)
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.
Trial: NCT02093663
Drug: MMX Mesalamine/Mesalazine (High Dose)
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
Trial: NCT00247988
Drug: Weekly Taxotere with weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03396484
Drug: Methyldopa
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral dosing
Trial: NCT01391325
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
Trial: NCT00981747
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
Trial: NCT03240523
Drug: Vilaprisan (BAY1002670)
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, 2 mg, once daily
Trial: NCT02910570
Drug: Liraglutide 3 mg (Saxenda)
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
Trial: NCT02910570
Drug: Liraglutide 3 mg placebo
RxNorm normalized name: liraglutide 3.6 MG/ML
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
Trial: NCT01502137
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
Trial: NCT01502137
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
Trial: NCT01554176
Drug: Filorexant
RxNorm normalized name: Filorexant
DrugBank: Filorexant (DB12158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filorexant, one 10 mg tablet, orally, once daily at bedtime
Trial: NCT00981747
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
Trial: NCT02664922
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.